Treating High-Risk Early Breast Cancer in Patients on Adjuvant Therapy 
The FDA recently approved abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node-positive, early breast cancer with a high risk of recurrence. Read more.

How Receptive Are Persons Aged 80 and Older to BC Therapy?
It is estimated that over 11,000 persons aged >80 years died of breast cancer (BC) in 2019, and this number is only expected to increase with the graying of America. Unwillingness on the part of patient and/or provider and poor physical status often precludes the aggressive management in these patients, which can lead to unfavorable outcomes. Read more.

Weight Changes in BC Patients Based on Treatment Choices
Weight decreases or increases is often seen in breast cancer (BC) patients. This variability is due to differences in the study populations, cancer stage, definitions of weight change, and the time point at which weight change is measured. However, little is known about what effect treatment choices have on these fluctuations. Read more.